Listen "Tumor Mutational Burden in Small Cell Lung Cancer: A Valuable Biomarker for Immunotherapy? (BMIC-011)"
Episode Synopsis
Dr. Jack West reviews new findings highlighting the utility of using the biomarker tumor mutation burden (TMB) to predict which patients with small cell lung cancer (SCLC) will benefit from nivolumab or the combination of nivolumab with ipilimumab.
ZARZA We are Zarza, the prestigious firm behind major projects in information technology.